posted
I dont own any of this but i was curious if any of you know anything about it. I know some people who are into science and they say this company has submitted things for approval that would be major breakthroughs in treating cancer if they were approved. The person i talked to about it said that INGN spent a little more than a decade researching it and thinks it will be approved. Do any of u have thoughts on INGN?
IP: Logged |
posted
they are one of the first small bio-techs to get "fast trac" status on a drug (early 03 i think it was)... tripled in a couple days on that alone, but they are still in ph3 trials. there is ALWAYS a risk that it won't get approved....the company is releasing very positive PR's...but they burn a LOT of cash, so they have to get funding...
IF it gets approved?...5X EZ maybe 10X in a day...
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
do you really think a stock that is around 7 could go up that much in one day. i thought only the little penny stocks were capable of jumps like that in one day
IP: Logged |
posted
oh yeah, i have had a couple do it...been awhile tho..last non-penyy that i got a good thrill-ride out of was OSIP..bought in around the same time as this one too...motley fool was pumping it back in early '03...i guess it wasn't quite a 5xer in one day now that i look at the chart, but, it did it quick...
darn, it's been almost a year......hmm i must must be slippin' or the market must be bad...
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
INGN looks promising, but i have to warn you that bio-tech and FDA aproval can be a real heart-breaker. martha Stewart was burned on one, the FDA refused to aprove the drug , she sold( insider trade?) and then the FDA turned around later on and APPROVED the very same drug...go figure...
and in this case i BELIEVE it's ALL or NUTT'N on one drug..
SQNM i got into at the same time and they are way down right now...
[ January 24, 2005, 23:17: Message edited by: glassman ]
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
i see... Yeah im just a high school student and i really like the stock market. Im thinking of trying to make a living in it but i guess i need to get a little better at it and see if i can tolerate spending that many hours working with it every day. how long have you been doing this for?
IP: Logged |
posted
i started buying stock with my paper route money in the early 70's my family helped me...
i bought local power company stocks DIRECTLY from the power co. (NO broker fees) set up the accounts on AUTO dividend re-investment....after a while you start to get some REAL savings...
there's no get-rich quick here...yes, there are GREAT days, and in a GREAT market they come frequently, but the faster you try to make it? the faster you CAN lose it....you need some deep reserves to take BIG risks...
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
Yeah i started in around the 6th grade. I was a real penny pincher when i was little i never spent any money no matter what i got or who i got it from. by the time i was in the 6th grade i had about 500 dollars and i put it in dell. I live in Austin so that was the local company that i knew a little bit about. Maybe some day i will be doing this and decide i want to blow glass for a living as well
IP: Logged |
posted
Introgen's INGN 241 Works Synergistically With Celebrex(R) to Kill Breast Cancer Cells Tuesday November 8, 3:41 pm ET
AUSTIN, Texas, Nov. 8 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex®) marketed by Pfizer (NYSE: PFE - News) to inhibit the growth and increase apoptosis (cell death) of breast cancer cells. A team of researchers led by Kelly Hunt, M.D., chief, Surgical Breast Section in the Department of Surgical Oncology at M.D. Anderson Cancer Center, Introgen and the Catholic University of Korea conducted the studies, and the data appear in the current issue of the medical journal Surgery. These data demonstrate the potential utility of INGN 241 in combination with celecoxib, a drug approved for the treatment of pre-cancerous lesions of the colon, and exemplify the increase in understanding of the effects of INGN 241 on multiple cancer-related pathways. Results of this study may help in designing new low-toxicity treatment strategies that combat breast cancer. ADVERTISEMENT
Celecoxib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of arthritis and is also approved as the first drug therapy for patients with familial adenomatous polyposis (FAP). FAP is a genetic condition that, if left untreated, almost invariably results in colon cancer.
"The multiple pathways through which INGN 241 exerts its anti-cancer effects support its development as a new cancer treatment that combines the safety and efficacy of a targeted therapy with the broad utility of standard treatment regimens. In this study, we demonstrate the synergistic activity between INGN 241 and celecoxib in killing breast cancer cells. Combining two low toxicity agents may provide additional options for breast cancer patients," said Sunil Chada, Ph.D., Introgen's associate vice president, Clinical Research, and an author on the paper.
Previous studies have shown that celecoxib and INGN 241 work as single agents to inhibit growth and increase killing of cultured breast cancer cells. Celecoxib inhibits COX-2, an important enzyme that is associated with cancer progression and can also regulate the cell survival pathways. Because related cell survival pathways are also a target of mda-7, the active component of INGN 241, studies were undertaken to evaluate the effects of simultaneously inhibiting these pathways in human breast cancer cells.
Results showed that INGN 241, celecoxib and the combination markedly inhibited cell growth compared with controls. The combination of celecoxib and INGN 241 showed greater than additive increases in cell death compared with either therapy alone, and also resulted in the suppression of tumor cell growth. The effectiveness of INGN 241 in combination with celecoxib reported in these studies and the favorable safety profile of INGN 241 observed in clinical trials to date support additional study of this regimen as a novel breast cancer therapy.
The mda-7 gene was discovered by the laboratory of Dr. Paul B. Fisher, professor of clinical pathology at Columbia University. Introgen holds an exclusive worldwide license for all gene therapy applications from the Corixa Corporation. INGN 241 is an investigational cancer therapy currently being evaluated in a Phase 2 study in patients with metastatic melanoma.
A small subset of patients may have increased risk of cardiovascular side effects when taking COX-2 inhibitors like celecoxib. This small risk may be acceptable for cancer patients with unmet medical needs depending upon the potential benefits of celecoxib therapy.
Introgen holds a licensing agreement with M. D. Anderson to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas System Board of Regents own stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its clinical development program for treatment of cancer or other diseases and relating to INGN 241 and its development as a monotherapy, as part of combination regimens, as an anti-angiogenic agent and as an immunotherapy. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke*introgen.com
posted
as i noted in a early post i took them from 3.oo and got out at 9.00 i think in a matter of six months. ingn is alreadry making another run. there lot good press out recently and more to come.albatross
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
